Delphine Charvin, PhD, has been working at Prexton Therapeutics since its inception, overseeing Prexton’s biological activities, from characterization of mode of action in vitro to nomination of clinical candidate nomination, going through characterization of drug properties.

Prior to joining Prexton, Dr. Charvin was senior scientist and project leader in the Parkinson’s disease department of Merck-Serono. From 2008 to 2010, she was laboratory head and biology project leader in the central nervous system business unit of Addex Pharmaceuticals, leading among other programs, biology activities of the mGluR4 PAM project. During her successive experience in drug discovery, Dr. Charvin led multi-disciplinary programs that successfully identified and characterized novel allosteric modulators of various targets, for various neurological indications, including Parkinson’s disease.

Dr. Charvin received her PhD in neuroscience from the University Paris VI, France, and completed her postdoctoratal training in Pr Aebischer’s laboratory at EPFL, Switzerland.